Van Puyvelde Joeri, Meyns Bart, Rega Filip, Gewillig Marc, Eyskens Benedicte, Heying Ruth, Cools Bjorn, Salaets Thomas, Hellings Peter-William, Meuris Bart
Department of Cardiovascular Sciences, KU Leuven, Leuven, Belgium.
Department of Cardiac Surgery, University Hospitals Leuven, Leuven, Belgium.
Interdiscip Cardiovasc Thorac Surg. 2024 Mar 5;38(3). doi: 10.1093/icvts/ivae034.
To investigate if there is still a place for bioprosthetic mitral valve replacement in children by comparing the prosthetic durability and transplant-free survival after bioprosthetic and mechanical mitral valve replacement.
We reviewed all mitral valve replacements in children between 1981 and 2020. Bioprosthetic mitral valve replacement cases were individually matched to mechanical mitral valve replacement cases. The incidence rate of a 2nd replacement was calculated using the cumulative incidence function that considered death or transplantation as a competing risk.
The median age at implantation was 3.6 years (interquartile range 0.8-7.9) for the bioprosthetic valve cohort (n = 28) and 3 years (interquartile range 1.3-7.8) for the mechanical valve cohort (n = 28). Seven years after bioprosthetic mitral valve replacement, the cumulative incidence of death or transplantation was 17.9% [95% confidence interval (CI) 6.3-34.1] and the cumulative incidence of a 2nd replacement was 63.6% (95% CI 39.9-80.1). Seven years after mechanical mitral valve replacement, the cumulative incidence of death or transplantation was 28.6% (95% CI 13.3-46) and the cumulative incidence of a 2nd replacement was 10.7% (95% CI 2.6-25.5). Fifteen years after mechanical mitral valve replacement, the cumulative incidence of death or transplantation was 33.6% (95% CI 16.2-52.1) and the cumulative incidence of a 2nd replacement was 41.1% (95% CI 18.4-62.7). The cumulative incidence curves for bioprosthetic and mechanical mitral valve replacement were statistically different for a 2nd valve replacement (P < 0.001) but not for death or transplantation (P = 0.33).
There is no difference in transplant-free survival after bioprosthetic and mechanical mitral valve replacement in children. The lifespan of bioprosthetic mitral valves remains limited in children because of structural valve failure due to calcification. After 15 years, 40% of mechanical valves were replaced, primarily because of patient-prosthesis mismatch related to somatic growth.
通过比较生物瓣和机械瓣二尖瓣置换术后的假体耐久性和无移植生存率,探讨生物瓣二尖瓣置换术在儿童中是否仍有应用价值。
我们回顾了1981年至2020年间所有儿童二尖瓣置换病例。生物瓣二尖瓣置换病例与机械瓣二尖瓣置换病例进行个体匹配。使用将死亡或移植视为竞争风险的累积发病率函数计算二次置换的发病率。
生物瓣队列(n = 28)的植入时中位年龄为3.6岁(四分位间距0.8 - 7.9),机械瓣队列(n = 28)为3岁(四分位间距1.3 - 7.8)。生物瓣二尖瓣置换术后7年,死亡或移植的累积发病率为17.9%[95%置信区间(CI)6.3 - 34.1],二次置换的累积发病率为63.6%(95% CI 39.9 - 80.1)。机械瓣二尖瓣置换术后7年,死亡或移植的累积发病率为28.6%(95% CI 13.3 - 46),二次置换的累积发病率为10.7%(95% CI 2.6 - 25.5)。机械瓣二尖瓣置换术后15年,死亡或移植的累积发病率为33.6%(95% CI 16.2 - 52.1),二次置换的累积发病率为41.1%(95% CI 18.4 - 62.7)。生物瓣和机械瓣二尖瓣置换的二次瓣膜置换累积发病率曲线在统计学上有差异(P < 0.001),但在死亡或移植方面无差异(P = 0.33)。
儿童生物瓣和机械瓣二尖瓣置换术后的无移植生存率无差异。由于钙化导致的结构性瓣膜功能障碍,儿童生物瓣二尖瓣的使用寿命仍然有限。15年后,40%的机械瓣被置换,主要是因为与身体生长相关的患者 - 假体不匹配。